New Vista Acquisition Corp *W EXP 02/01/2026
Change company Symbol lookup
Select an option...
NVSAW New Vista Acquisition Corp *W EXP 02/01/2026
$R25IGTRI Russell 2500 Growth TR Index
QQQ Invesco QQQ Trust
PRDO Perdoceo Education Corp
DITHF DS Smith PLC
BIOL BIOLASE Inc
GOEV Canoo Inc
CHE Chemed Corp
ASTA WorldFlix Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
Go

Company profile

New Vista Acquisition Corp is a blank check company. The Company is crested for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is focused on aviation, aerospace and defense industries. The Company has no operations and has not generated revenues.

Closing Price
$0.73
Day's Change
0.0001 (0.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.73
Day's Low
0.70
Volume
(Light)
Volume:
10,138

10-day average volume:
17,934
10,138

Jasper Therapeutics' stock more than doubles after Oppenheimer analyst's bullish call

10:12 am ET October 13, 2021 (MarketWatch)
Print

Shares of Jasper Therapeutics Inc. (JSPR) soared 106.2% in volatile morning trading, enough to pace the Nasdaq's gainers, after Oppenheimer analyst Jay Olson's bullish endorsement the day after the stock closed at a record low. The stock had been halted for volatility twice in the first half hour after the open, as trading volume swelled to 20.7 million shares. The company started trading as a biotechnology company with its "JSPR" ticker after the closing of the acquisition by special purpose acquisition company (SPAC) Amplitude Healthcare Acquisition Corp. was announced after the Sept. 24 close. From that day through Tuesday, the stock had plunged 52.3%, while the S&P 500 slipped 2.4% over the same time. Oppenheimer's Olson initiated Jasper with an outperform rating and stock price target of $21, implying a further 41% gain from current levels. "We view [Jasper] as an emerging leader in the development of novel targeted conditioning agents for hematopoietic stem cell transplantation (HSCT) with lead candidate JSP191 and proprietary engineered hematopoietic stem cell (eHSC) platform," Olson wrote in a note to clients.

-Tomi Kilgore

	

(END) Dow Jones Newswires

October 13, 2021 10:12 ET (14:12 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.